Aufgepasst!:
Ab jetzt dynaCERT statt Bitcoin oder NVIDIA?
Anzeige

AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

2,53 EUR
+3,69 %+0,09
25. Nov, 19:55:32 Uhr, Baader Bank
Kommentare 608
M
Magelan, 14.11.2019 11:10 Uhr
0
Hast du irgendwelche Infos
S
Streuselinho, 14.11.2019 10:05 Uhr
0
Erst bei 0,3 wieder :)
M
Magelan, 14.11.2019 6:11 Uhr
0
Bei dem Wert werde ich heute nachlegen
Li27
Li27, 13.11.2019 11:41 Uhr
0
da ich letzte Woche verdoppelt habe bin ich jetzt etwas im Minus... aber die Richtung auf lange Sicht ist entscheidend.
S
Streuselinho, 13.11.2019 8:53 Uhr
0
Es ist und bleibt ein volatiler pennystock.
M
Magelan, 13.11.2019 7:16 Uhr
0
Puhh was ist den los, habe was anderes erwartet
odi001
odi001, 13.11.2019 4:31 Uhr
0
ASX/News Release AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, including optimizing support for clinical trials and development projects, as well as the Company’s continued U.S. commercial growth strategy. The Institutional Placement was managed by Bell Potter as sole lead manager. Cowen served as financial advisor to the Company in connection with the Institutional Placement. Lake Street Capital Markets also acted as a financial advisor to Avita Medical. The Company has received commitments for A$120.0 million at an issue price of A$0.59 per fully paid ordinary share, representing a 7.2 percent discount to the 30-day VWAP, and a 14.5 percent discount to the last closing price on 8 November 2019. The new AVITA shares to be issued under the Institutional Placement will rank equally with existing AVITA shares on issue. The Institutional Placement will occur in a single tranche, and issue 203,389,831 shares to international and Australian sophisticated investors under its 15 percent placement capacity (under ASX Listing Rule 7.1). “We are grateful for the confidence and conviction of the investors who have joined us in our mission to transform burn care with our revolutionary RECELL® System and to promptly execute on our pipeline of add-on indications,” said Dr. Mike Perry, Chief Executive Officer. “This financing reflects our shared excitement for, and strong confidence in, AVITA Medical’s myriad near-term growth opportunities. These include trauma/soft tissue reconstruction, vitiligo, our next generation RECELL device to facilitate use of the RECELL System in the outpatient setting, and pediatric scald wounds, as well as efforts to enable research programs to support the advancement and extension of our existing intellectual property. Through diligent and focused execution on our highly de-risked pipeline of new indications, we have the opportunity to access the full potential of our innovative regenerative medicine platform to advance patient care that addresses unmet medical needs, while aggressively growing our top *** revenues and ultimately building a robust self-sustaining business.” Accelerating pipeline development The funds from the Institutional Placement will enable AVITA Medical to fast-track progression of clinical development programs and to accelerate its broader commercialization strategy. Key initiatives include: • Initiating U.S. pivotal trials to establish the safety and efficacy of the RECELL System in soft tissue reconstruction and traumatic wounds, as well as early intervention in the treatment of pediatric scald wounds • Further development and submission to the FDA of a next generation RECELL System to facilitate access to the large outpatient market • Pilot studies with the RECELL System for the treatment of vitiligo, and subsequent rapid advancement into a pivotal clinical trial to secureadva this indication in the U.S. For personal use only
D
DividendenJoe, 12.11.2019 16:23 Uhr
0
Ok top, danke 👍
M
Magelan, 12.11.2019 14:26 Uhr
0
eVo99 => weil Avita ins ASX200 rauf rutscht
Willilex64
Willilex64, 12.11.2019 12:43 Uhr
0
Danke
D
DividendenJoe, 12.11.2019 12:36 Uhr
0
Warum?
odi001
odi001, 12.11.2019 11:55 Uhr
0
Vom Handel bis 14. 11 ausgesetzt
Willilex64
Willilex64, 12.11.2019 9:47 Uhr
0
Keine Bewegung seit Freitag?
odi001
odi001, 12.11.2019 6:23 Uhr
0
https://***.com.au/threads/powerful-cocktail.5066983/page-8?post_id=41379894 h.o.t.c.o.p.p.e.r
odi001
odi001, 11.11.2019 12:35 Uhr
0
https://www.afr.com/street-talk/avita-medical-raising-100-million-20191111-p539e7
Li27
Li27, 11.11.2019 9:08 Uhr
0
🚀🚀🚀
Meistdiskutiert
Thema
1 RENK (für normale, sachliche Kommunikation!) -4,40 %
2 NVIDIA Hauptdiskussion -4,21 %
3 PLUG POWER Hauptdiskussion +14,16 %
4 ATOS Hauptdiskussion +128,32 %
5 PAIN THERAPEUTICS Hauptdiskussion -87,00 %
6 Diskussion zur BICO Group Aktie +6,05 %
7 TESLA MOTORS Hauptdiskussion -2,08 %
8 MicroStrategy -5,10 %
9 DPCM Capital Hauptdiskussion -10,30 %
10 BAYER Hauptdiskussion +0,51 %
Alle Diskussionen
Aktien
Thema
1 RENK (für normale, sachliche Kommunikation!) -4,40 %
2 NVIDIA Hauptdiskussion -4,21 %
3 ATOS Hauptdiskussion +128,32 %
4 PAIN THERAPEUTICS Hauptdiskussion -87,00 %
5 Diskussion zur BICO Group Aktie +6,05 %
6 PLUG POWER Hauptdiskussion +14,16 %
7 TESLA MOTORS Hauptdiskussion -2,08 %
8 MicroStrategy -5,10 %
9 DPCM Capital Hauptdiskussion -10,30 %
10 BAYER Hauptdiskussion +0,51 %
Alle Diskussionen